Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors

Emiel Leegwater; Anne Strik; Erik B Wilms; Liesbeth B E Bosma; David M Burger; Thomas H Ottens; Cees van Nieuwkoop

doi:10.1093/cid/ciaa883

Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors

Clin Infect Dis. 2021 Apr 8;72(7):1256-1258. doi: 10.1093/cid/ciaa883.

Authors

Emiel Leegwater^{1

2}, Anne Strik³, Erik B Wilms^{1

2}, Liesbeth B E Bosma¹, David M Burger⁴, Thomas H Ottens⁵, Cees van Nieuwkoop³

Affiliations

¹ Department of Hospital Pharmacy, Haga Teaching Hospital, The Hague, The Netherlands.
² The Hague Hospital Pharmacy, The Hague, The Netherlands.
³ Department of Internal Medicine, Haga Teaching Hospital, The Hague, The Netherlands.
⁴ Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
⁵ Department of Intensive Care, Haga Teaching Hospital, The Hague, The Netherlands.

Abstract

We report a case of a man with COVID-19 who developed acute hepatotoxicity related to remdesivir with probable interaction of P-glycoprotein (P-gp) inhibitors. Until further details on this interaction become available, we recommend physicians to be cautious with the prescription of P-gp inhibitors in patients receiving remdesivir therapy.

Keywords: COVID-19; drug–drug interaction; hepatotoxicity; remdesivir.

Publication types

Case Reports

MeSH terms

ATP Binding Cassette Transporter, Subfamily B
Adenosine Monophosphate / analogs & derivatives
Alanine / analogs & derivatives
Antiviral Agents / adverse effects
COVID-19 Drug Treatment*
Chemical and Drug Induced Liver Injury* / etiology
Humans
Male
SARS-CoV-2

Substances

ATP Binding Cassette Transporter, Subfamily B
Antiviral Agents
remdesivir
Adenosine Monophosphate
Alanine